Known targets — ChEMBL curated mechanism
ACVRL1MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Panulisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 16/20 | 0.48 |
| ▸ | MTOR known ✓ | P42345 | 13/20 | 0.48 |
| ▸ | PIK3CD known ✓ | O00329 | 10/20 | 0.48 |
| ▸ | PIK3CG known ✓ | P48736 | 8/20 | 0.48 |
| ▸ | PIK3CB known ✓ | P42338 | 7/20 | 0.48 |
| ▸ | PIK3R1 known ✓ | P27986 | 1/20 | 0.46 |
| ▸ | PIK3R5 known ✓ | Q8WYR1 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 2/20 | 0.46 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.46 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.46 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.46 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | LTK | P29376 | 1/20 | 0.46 |
| ▸ | CDK7 | P50613 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Panulisib SCHEMBL30157179 | 1.00 | PIK3CA (0.48) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| Panulisib SCHEMBL29397330 | 1.00 | PIK3CA (0.48) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| Panulisib SCHEMBL29368897 | 1.00 | PIK3CA (0.48) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| Panulisib SCHEMBL367229 | 1.00 | PIK3CA (0.48) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| Panulisib SCHEMBL16714451 | 1.00 | PIK3CA (0.48) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL16726550 | 0.94 | PIK3CA (0.47) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL368584 | 0.94 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL368585 | 0.94 | PIK3CA (0.45) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL369057 | 0.91 | PIK3CA (0.56) | PIK3CAMTORPIK3CDPIK3CGPIK3CB | |
| SCHEMBL369058 | 0.91 | PIK3CA (0.56) | PIK3CAMTORPIK3CDPIK3CGPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | claimed |
| US-20230255974-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2023-08-17 | — | — | US | claimed |
| WO-2015145369-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED IMIDAZO[4,5-C]QUINOLINE COMPOUNDS, INTERMEDIATES AND POLYMORPHS THEREOF | Piramal Enterprises Limited (IN) | 2015-10-01 | — | — | WO | claimed |
| WO-2014177915-A1 | CANCER COMBINATION THERAPY USING IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2014-11-06 | — | — | WO | claimed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | claimed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | claimed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | claimed |
| EP-3523331-B1 | CHIMERIC ANTIGEN RECEPTORS FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | NOVARTIS AG (CH) | 2026-04-07 | — | — | US | disclosed |
| EP-4706773-A2 | HUMAN MESOTHELIN CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | Novartis AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | UNIV OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2025-12-04 | — | — | US | disclosed |
| US-12344657-B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | NOVARTIS AG (CH) | 2025-07-01 | — | — | US | disclosed |
| US-9062046-B2 | Substituted imidazoquinoline derivatives as kinase inhibitors | Piramal Enterprises Limited (IN) | 2015-06-23 | — | — | US | disclosed |
| US-20150140036-A1 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| WO-2015073644-A1 | MTOR INHIBITORS FOR ENHANCING THE IMMUNE RESPONSE | NOVARTIS AG (CH) | 2015-05-21 | — | — | WO | disclosed |
| WO-2014177915-A1 | CANCER COMBINATION THERAPY USING IMIDAZO[4,5-C]QUINOLINE DERIVATIVES | Piramal Enterprises Limited (IN) | 2014-11-06 | — | — | WO | disclosed |
| EP-2593450-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-22 | — | — | EP | disclosed |
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | Piramal Enterprises Limited (IN) | 2013-05-09 | — | — | US | disclosed |
| WO-2012007926-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116248-A1 | SUBSTITUTED IMIDAZOQUINOLINE DERIVATIVES AS KINASE INHIBITORS | CDK2, CDK4, MAP3K1 | PIK3CA 72/4885MTOR 102/4885PIK3CD 115/4885 |
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | PTPRCAP, PTPRC, CD47 | PIK3CA 759/4885MTOR 2307/4885PIK3CD 478/4885 |
| US-12344657-B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | CD22, CD2, CD99 | PIK3CA 2991/4885MTOR 3162/4885PIK3CD 2624/4885 |
| US-12594321-B2 | Bispecific chimeric antigen receptor that binds CD19 and CD20, encoding nucleic acid molecules thereof and methods of use thereof to treat cancer | CD2, CD22, KLRK1 | PIK3CA 1947/4885MTOR 3931/4885PIK3CD 983/4885 |
| US-20260053761-A1 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | THRA, THRB, TRHR | PIK3CA 2438/4885MTOR 4538/4885PIK3CD 2996/4885 |
| US-20150140036-A1 | LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOF | MTOR, RICTOR, RPTOR | PIK3CA 62/4885MTOR 1/4885PIK3CD 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.